Edwards Lifesciences Reports Third Quarter Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/24/2026
- S&P 500, Nasdaq slip as Iran tensions test markets in high-stakes week
- Oil falls ahead of US announcement of new sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Wattmore and Eos Energy strike non-exclusive storage software deal
- S&P 500, Nasdaq slip as Iran tensions test markets in high-stakes week
- RUM Group signs $13.7 billion GPU services deal, issues warrants
- XPeng Inc. (XPEV) Misses Q2 EPS by 100c ; Provides Outlook
- Funds sell $44bn in semiconductors on AI concerns
Canaccord Genuity Reiterates Buy on Edwards Lifesciences (EW) following 3Q Results
October 27, 2015 10:50 AM EDTCanaccord Genuity reiterated a Buy rating on Edwards Lifesciences (NYSE: EW), and raised the price target to $180.00 (from $178.00), following the company's 3Q earnings results. EW reported EPS of $1.07, beating consensus by 9c. Management does an excellent job hedging FX swings to neutralize EPS... More
UBS Raises Price Target on Edwards Lifesciences (EW) Following Strong 3Q Results
October 27, 2015 8:57 AM EDTUBS reiterated a Buy rating on Edwards Lifesciences (NYSE: EW), and raised the price target to $203.00 (from $201.00), following the company's 3Q15 earnings results. Management upped fullyear EPS guidance by $4.43-4.53 from $4.30-4.40, which assumes a touch more upside in Q4.
Analyst Matt Miksic... More
Edwards Lifesciences (EW) Tops Q3 EPS by 9c, Q4 & FY Guidance Tops Views
October 26, 2015 4:18 PM EDTEdwards Lifesciences (NYSE: EW) reported Q3 EPS of $1.07, $0.09 better than the analyst estimate of $0.98. Revenue for the quarter came in at $615 million versus the consensus estimate of $598.29 million.
Edwards Lifesciences sees FY2015 EPS of $4.43-$4.53, versus the consensus of $4.37. Edwards Lifesciences sees FY2015... More
